Beta-blockade at low doses restoring the physiological balance in myocytic antagonism

European Journal of Cardio-thoracic Surgery

Volumn 32, Issue 2, 2007, Pages 225-230

  Lunkenheimer, Paul P ^a   Redmann, Klaus ^a   Cryer, Colin W ^a   Batista, Randas V ^b   Stanton, Jacobus J ^c   Niederer, Peter ^d   Anderson, Robert H ^e  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSIDADE ESTADUAL DE RORAIMA   (Brazil)

^c STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^d UNIVERSITY OF ZURICH   (Switzerland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Auxotonic forces; Beta blockade; Intrinsic antagonism; Unloading forces

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESMOLOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; HEART RATE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE WALL; HUMAN; INOTROPISM; MALE; MUSCLE CELL; OPEN HEART SURGERY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE;

EID: 34347388599     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2007.03.048     Document Type: Article

References (10)

1. Lunkenheimer P.P., Redmann K., Florek J., Fassnacht U., Cryer C.W., Wübbeling F., Niederer P., and Anderson R.H. The forces generated within the musculature of the left ventricular wall. Heart 90 (2004) 200-207
2. Anderson R.H., Ho S.Y., Sanchez-Quintana D., Redmann K., and Lunkenheimer P.P. Heuristic problems in defining the three-dimensional arrangement of the ventricular myocytes. Anat Rec 288 (2006) 579-586
3. Lunkenheimer P.P., Redmann K., Kling N., Jiang X., Rothaus K., Cryer C.W., Wübbeling F., Niederer P., Heitz P.U., Ho S.Y., and Anderson R.H. The three-dimensional architecture of the left ventricular myocardium. Anat Rec Part A 288A (2006) 565-578
4. Byred R.L., Sung R.J., Marks J., and Parmley W.W. Safety and efficacy of Esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll Cardiol 3 (1984) 394-399
5. The Beta-Blocker Evaluation of Survival Trial Investigators (BEST). BEST writing committee. A trial of the beta-blocker Bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67.
6. Bristow M.R., Gilbert E.M., Abraham W.T., Adams K.F., Fowler M.B., Hershberger R.E., Kubo S.H., Narahara K.A., Ingersoll H., Krueger S., Young S., and Shusterman N. Carvedolol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 94 (1996) 2907-2916
7. Eichhorn E.J., Domanski M.J., Krause-Steinrauf H., Bristow M.R., and Lavori PhW. A trial of the beta-blocker Bucindolol in patients with advanced chronic heart failure. The Beta-Blocker Evaluation of Survival Trial Investigators. N Engl J Med 344 (2001) 1659-1667
8. Freudenberger R., Kalman J., Mannino M., Buchholz-Varley C., Ocampo O., and Kukin M. Effect of race in the response to metoprolol in patients with congestive heart failure secondary to idiopathic dilated or ischemic cardiomyopathy. J Am Coll Cardiol 80 (1997) 1372-1374
9. Gardner R.S., Martin W., Carter R., and McDonagh T.A. Importance of β-blockade in the treatment of advanced heart failure. Heart 89 (2003) 1442-1444
10. Lunkenheimer P.P., Redmann K., Kimaun D., Cryer C.W., Wübbeling F., Konertz W., Zytowsky A., Hotz H., Ho S.Y., and Anderson R.H. A critical evaluation of results of partial ventriculectomy. J Card Surg 18 (2003) 225-235